{
    "clinical_study": {
        "@rank": "80615", 
        "arm_group": {
            "arm_group_label": "Betanis  group", 
            "description": "Patients receiving Betanis for Overactive Bladder"
        }, 
        "brief_summary": {
            "textblock": "This study is to determine the following information.\n\n        1. The occurrence of adverse drug reactions in clinical settings.\n\n        2. Factors potentially impacting safety, effectiveness, and other aspects."
        }, 
        "brief_title": "Drug Use-Results Survey of Betanis Tablets in Japan", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "detailed_description": {
            "textblock": "This survey aims to determine the following information and the need for conducting\n      specified drug use-results surveys and post-marketing clinical studies in patients using\n      Betanis (generic name: mirabegron):\n\n        1. The occurrence of adverse drug reactions in clinical settings.\n\n        2. Factors potentially impacting safety, effectiveness, and other aspects.\n\n      Items of Particular Interest:\n\n        -  Safety and effectiveness in patients with hepatic impairment and patients with renal\n           impairment.\n\n        -  Safety and effectiveness when mirabegron is used concomitantly with other drugs (\u03b11\n           blockers, anticholinergic agents, 5\u03b1 reductase inhibitors, drugs with a potent\n           CYP3A4-inhibiting effect, drugs with a CYP3A4-inducing effect, drugs metabolized\n           primarily by CYP2D6, and other frequently used drugs).\n\n        -  The occurrence of cardiovascular adverse events.\n\n        -  The occurrence of adverse events related to increased intraocular pressure.\n\n        -  The occurrence of urinary retention"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who received mirabegron for the first time for the treatment of urinary\n             urgency, daytime frequency, and urgency incontinence associated with overactive\n             bladder."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who received mirabegron for the first time for the treatment of urinary urgency,\n        daytime frequency, and urgency incontinence associated with overactive bladder."
            }
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919047", 
            "org_study_id": "BE0001"
        }, 
        "intervention": {
            "arm_group_label": "Betanis  group", 
            "description": "Oral", 
            "intervention_name": "Betanis", 
            "intervention_type": "Drug", 
            "other_name": [
                "Mirabegron", 
                "YM178"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "overactive bladder", 
            "mirabegron", 
            "occurrence of adverse events", 
            "Overactive Bladder Symptom Score"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Touhoku", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Use-Results Survey of Betanis Tablets 25 and 50 mg", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Central Contact", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of adverse events and adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919047"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in OABSS (overactive bladder symptom score)", 
                "safety_issue": "No", 
                "time_frame": "baseline and at 12 weeks (or last observation period)"
            }, 
            {
                "measure": "Items of particular interest", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and at 12 weeks (or last observation period)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}